Arrowhead Research reported $1.29B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 28.75B 1.4B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
TG Therapeutics USD 1.17B 25.76M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026